Outcome of COVID-19 patients treated with VV-ECMO in Tyrol during the pandemic.

IF 1.9 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Wiener Klinische Wochenschrift Pub Date : 2024-08-01 Epub Date: 2023-11-10 DOI:10.1007/s00508-023-02301-5
Andreas Peer, Fabian Perschinka, Georg Lehner, Timo Mayerhöfer, Peter Mair, Juliane Kilo, Robert Breitkopf, Dietmar Fries, Michael Joannidis
{"title":"Outcome of COVID-19 patients treated with VV-ECMO in Tyrol during the pandemic.","authors":"Andreas Peer, Fabian Perschinka, Georg Lehner, Timo Mayerhöfer, Peter Mair, Juliane Kilo, Robert Breitkopf, Dietmar Fries, Michael Joannidis","doi":"10.1007/s00508-023-02301-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>A small percentage of patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2) showed severe respiratory deterioration requiring treatment with extracorporeal membrane oxygenation (ECMO). During the pandemic surges availability of ECMO devices was limited and resources had to be used wisely. The aim of this analysis was to determine the incidence and outcome of venovenous (VV) ECMO patients in Tyrol, when criteria based on the Extracorporeal Life Support Organization (ELSO) guidelines for VV-ECMO initiation were established.</p><p><strong>Methods: </strong>This is a secondary analysis of the Tyrol-CoV-ICU-Reg, which includes all patients admitted to an intensive care unit (ICU) during the coronavirus disease 2019 (COVID-19) pandemic in Tyrol. Of the 13 participating departments, VV-ECMO was performed at 4 units at the University Hospital Innsbruck.</p><p><strong>Results: </strong>Overall, 37 (3.4%) of 1101 patients were treated with VV-ECMO during their ICU stay. The hospital mortality rate was approximately 40% (n = 15). Multiorgan failure due to sepsis was the most common cause of death. No significant difference in survival rates between newly initiated and experienced centers was observed. The median survival time of nonsurvivors was 27 days (interquartile range, IQR: 22-36 days) after initiation of VV-ECMO. Acute kidney injury meeting the Kidney Disease: Improving Global Outcomes (KDIGO) criteria occurred in 48.6%. Renal replacement therapy (RRT) was initiated in 12 (32.4%) patients after a median of 18 days (IQR: 1-26 days) after VV-ECMO start. The median length of ICU and hospital stays were 38 days (IQR: 30-55 days) and 50 days (IQR: 37-83 days), respectively.</p><p><strong>Discussion: </strong>Despite a rapidly increased demand and the resulting requirement to initiate an additional ECMO center, we could demonstrate that a structured approach with interdisciplinary collaboration resulted in favorable survival rates similar to multinational reports.</p>","PeriodicalId":23861,"journal":{"name":"Wiener Klinische Wochenschrift","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11327186/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wiener Klinische Wochenschrift","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00508-023-02301-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: A small percentage of patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2) showed severe respiratory deterioration requiring treatment with extracorporeal membrane oxygenation (ECMO). During the pandemic surges availability of ECMO devices was limited and resources had to be used wisely. The aim of this analysis was to determine the incidence and outcome of venovenous (VV) ECMO patients in Tyrol, when criteria based on the Extracorporeal Life Support Organization (ELSO) guidelines for VV-ECMO initiation were established.

Methods: This is a secondary analysis of the Tyrol-CoV-ICU-Reg, which includes all patients admitted to an intensive care unit (ICU) during the coronavirus disease 2019 (COVID-19) pandemic in Tyrol. Of the 13 participating departments, VV-ECMO was performed at 4 units at the University Hospital Innsbruck.

Results: Overall, 37 (3.4%) of 1101 patients were treated with VV-ECMO during their ICU stay. The hospital mortality rate was approximately 40% (n = 15). Multiorgan failure due to sepsis was the most common cause of death. No significant difference in survival rates between newly initiated and experienced centers was observed. The median survival time of nonsurvivors was 27 days (interquartile range, IQR: 22-36 days) after initiation of VV-ECMO. Acute kidney injury meeting the Kidney Disease: Improving Global Outcomes (KDIGO) criteria occurred in 48.6%. Renal replacement therapy (RRT) was initiated in 12 (32.4%) patients after a median of 18 days (IQR: 1-26 days) after VV-ECMO start. The median length of ICU and hospital stays were 38 days (IQR: 30-55 days) and 50 days (IQR: 37-83 days), respectively.

Discussion: Despite a rapidly increased demand and the resulting requirement to initiate an additional ECMO center, we could demonstrate that a structured approach with interdisciplinary collaboration resulted in favorable survival rates similar to multinational reports.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新冠肺炎患者在大流行期间在蒂罗尔接受VV-ECMO治疗的结果。
简介:一小部分感染严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)的患者表现出严重的呼吸恶化,需要使用体外膜肺氧合(ECMO)进行治疗。在疫情激增期间,ECMO设备的可用性有限,必须明智地使用资源。当基于体外生命支持组织(ELSO)指南制定VV-ECMO启动标准时,本分析的目的是确定蒂罗尔静脉-静脉(VV)ECMO患者的发生率和结果。方法:这是对Tyrol-CoV-ICU-Reg的二次分析,包括2019年冠状病毒病(新冠肺炎)在Tyrol大流行期间入住重症监护室(ICU)的所有患者。在13个参与科室中,VV-ECMO在因斯布鲁克大学医院的4个病房进行。结果:1101名患者中,有37名(3.4%)在ICU期间接受了VV-ECMO治疗。住院死亡率约为40%(n = 15) 。败血症引起的多器官衰竭是最常见的死亡原因。新成立的中心和有经验的中心之间的存活率没有显著差异。VV-ECMO启动后,非幸存者的中位生存时间为27天(四分位间距,IQR:22-36天)。48.6%的患者出现了符合肾脏疾病:改善总体预后(KDIGO)标准的急性肾损伤。12名(32.4%)患者在VV-ECMO开始后的中位18天后(IQR:1-26天)开始了肾脏替代治疗(RRT)。ICU和住院时间的中位数分别为38天(IQR:30-55天)和50天(IQR 37-83天)。讨论:尽管需求迅速增加,因此需要建立一个额外的ECMO中心,但我们可以证明,跨学科合作的结构化方法产生了类似于多国报告的良好生存率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Wiener Klinische Wochenschrift
Wiener Klinische Wochenschrift 医学-医学:内科
CiteScore
4.70
自引率
3.80%
发文量
110
审稿时长
4-8 weeks
期刊介绍: The Wiener klinische Wochenschrift - The Central European Journal of Medicine - is an international scientific medical journal covering the entire spectrum of clinical medicine and related areas such as ethics in medicine, public health and the history of medicine. In addition to original articles, the Journal features editorials and leading articles on newly emerging topics, review articles, case reports and a broad range of special articles. Experimental material will be considered for publication if it is directly relevant to clinical medicine. The number of international contributions has been steadily increasing. Consequently, the international reputation of the journal has grown in the past several years. Founded in 1888, the Wiener klinische Wochenschrift - The Central European Journal of Medicine - is certainly one of the most prestigious medical journals in the world and takes pride in having been the first publisher of landmarks in medicine.
期刊最新文献
Gastrointestinal function and pain outcomes following segmental resection or discoid resection for low rectal endometriosis. Olfaction and thyroid hormones in patients with subjective cognitive decline, non-amnestic and amnestic mild cognitive impairment Neurofibromatosis type 1 adult surveillance form for Austria COVID-19 vaccines: anaphylaxis and anxiety Deciphering the role of lactate as a prognostic indicator in pediatric diabetic ketoacidosis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1